Journal of Experimental and Clinical Cancer Research Cover Letter

Weak: We identify a pathway that promotes tumor growth in cancer cells.

Stronger: We show that stromal IL-6 signaling creates a treatment-resistant state in EGFR-mutant lung tumors, and that pharmacologic interruption restores response in independent patient-derived models and a clinically annotated cohort.

The stronger opener names the mechanism, disease setting, clinical consequence, and the evidence that makes the bridge testable. It does not let a cell-line phenotype carry a therapeutic conclusion by itself.

Across our JECCR pre-submission reviews, the common difficulty is not whether a cancer result is interesting. It is whether the title, abstract, figures, patient-facing evidence, model choice, declarations, and letter support one credible translational route. The letter should make that route easy to inspect without asking an editor to infer it from broad oncology language.

Translational bridge is rhetorical

For Journal of Experimental & Clinical Cancer Research, a mechanistic result needs a visible consequence for prevention, diagnosis, treatment, resistance, prognosis, patient selection, or clinical understanding. State the decision or biological interpretation that changes, then point to the patient material, model, intervention, validation, or cohort that supports it.

Biomarker claim has no decision value

A signature, omics panel, or association can be useful but does not automatically establish a translational contribution. Say whether it changes risk assessment, treatment selection, resistance interpretation, target validation, or trial logic. If it does not, consider whether a narrower cancer-biology or resource route is more candid.

Therapeutic conclusion outruns the evidence

Do not label a pathway actionable solely because perturbation changes a cell-line assay. Name the disease model, validation level, control, limitation, and next claim the evidence actually supports. The letter can communicate scientific promise without presenting current draft readiness as clinical proof.

Declarations and conflicts are treated as afterthoughts

The official instructions require policy issues, competing interests, author approval, and an originality confirmation. Ensure these statements agree with the manuscript's Declarations section, ethics/consent language, data availability statement, funding, and submission fields. A concise, consistent record is more useful than a long generic assurance.

Reviewer identity is not verifiable

JECCR permits reviewer suggestions, requesting institutional email addresses where possible or ORCID/Scopus information that helps verify identity. Do not submit personal addresses, invented contacts, or strategically selected names with an undisclosed relationship. The guidance says intentional false reviewer information results in rejection and may prompt a misconduct investigation.

Lab-to-clinic claim is only a label. If the letter cannot state the patient, diagnostic, therapeutic, resistance, or prevention consequence without relying on a future study, it should narrow the claim. A narrower, fully supported mechanism is better than a clinical promise the data cannot yet carry.

Policy issue is hidden rather than explained. A material overlap, ethics limitation, data-access restriction, or special-issue context should be described concisely and consistently. Leaving the editor to discover it later makes an otherwise credible submission look less reliable.

Suggested reviewer is not independently checkable. Use the institutional email or identity record the official guidance requests. The purpose is verification and expertise matching, not an attempt to control who assesses the work.

The editorial question behind these patterns is whether the claim can survive the first read. A letter that names the cancer problem, translational route, evidence, and boundary helps the editor match the work to the right assessment. A letter that lists methods and calls them significant does not resolve fit.

Use the shortest honest chain that the manuscript can carry. A therapy-focused study might connect a defined tumor setting to a molecular vulnerability, show intervention evidence in more than one model, and explain what treatment-response question becomes more answerable. A biomarker study might connect a clinically defined cohort to a pre-specified endpoint, an independent validation set, and a realistic use case. A mechanism-first study can still fit when it explains why the mechanism changes an oncology problem rather than stopping at pathway activation.

The chain also marks the boundary. Cell lines can establish an early mechanistic result but cannot on their own establish patient benefit. A patient cohort can establish association but may not establish causation or treatment response. Animal data can strengthen a therapeutic hypothesis while remaining different from a clinical intervention. State the strongest supported conclusion, identify the validation that makes it credible, and do not turn a promising next experiment into a completed result in the letter.

For special issues, do not let the collection label replace this reasoning. Name the specific issue because the official guidance asks for it, then make the ordinary JECCR fit argument as well. For reviewer names, keep the recommendation separate from the scientific claim: an editor needs a transparent expertise match, not a signal that friendly reviewers have been assembled.

JECCR typically uses two or more independent experts to evaluate robustness, originality, and clarity. Reviewer suggestions may help identify expertise but are not a guarantee of selection. Because the journal operates single-anonymous review, editors and reviewers know author identities while reviewer reports to authors are anonymous.

Verify the current Editor-in-Chief on the journal's editorial-board page before quoting any name in a cover letter. Its listed APC is $4,490 USD, subject to applicable taxes and the rate in force on acceptance; fees belong in the budget decision, not the cover letter. Submit through the live Springer Nature portal. The same guidance sets a 15-word maximum for figure titles and 300 words for figure legends, useful checks when the letter points an editor to a key figure.

Read the title, abstract, first figure, and letter in sequence. Each should answer the same question: what cancer problem is changed, for whom or in which biological setting, and what evidence supports that consequence? Then compare every declaration in the letter against the manuscript and live submission fields. For a transfer or a revised manuscript, follow the portal's current route instead of trying to use the cover letter as a substitute for requested response files.

• JECCR submission guide